Ann: Mesoblast Update on Chronic Low Back Pain Program, page-203

Surgcentre would only participate to a modest degree, they are major players in the space, so not unreasonable, BUT not to a material degree, that could in any way, lead to wild and baseless claims of skewing a final result.

Very solid move by MSB and regulators, in both the US and EU, are very interested in avoiding unnecessary trial duplication wherever they can.

For example, ANP has recently announced the outcome of positive meetings with both the USFDA and EMA supporting a "harmonisation" of studies, in both the US and Europe, to help streamline and quicken drug candidate approval [if successful], regards their own soon to commence ATL1102  PhIII program.

So regulators on both sides of the Atlantic are open-minded to this type of thinking!